In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Canada’s unprecedented wildfire season
What on Earth is going on with consumer spending?
Violence is rising in schools. How do we stop it?
A warning sign from the Big Banks of a possible recession
Inside Kyiv under fire ahead of the Ukrainian counteroffensive
A divided Alberta: What comes next?
Emergency rooms in Canada head into another tough summer
The pandemic potential of avian flu
What Turkey’s election means for the rest of the world
You’re not wrong, allergies are getting worse
Why there won’t be a public inquiry into Chinese interference
The race to regulate artificial intelligence
Your upcoming flights might be cancelled, here’s why
Inside the greenhouse above the Arctic Circle
As Alberta burns, an election looms
Canada looks to India as ties with China fray
Is COVID over?
Why BlackBerry’s rise and fall still matters
The view from China on foreign interference in Canada
Canada’s extraordinary expulsion of a Chinese diplomat
Create your
podcast in
minutes
It is Free
Morning Wire
The Daily
Up First
Dobré ráno | Denný podcast denníka SME
Today, Explained